Leerink Partnrs Has Negative Outlook for IDXX Q3 Earnings

IDEXX Laboratories, Inc. (NASDAQ:IDXX) – Stock analysts at Leerink Partnrs reduced their Q3 2025 EPS estimates for IDEXX Laboratories in a research note issued on Thursday, May 1st. Leerink Partnrs analyst D. Clark now forecasts that the company will earn $3.03 per share for the quarter, down from their prior forecast of $3.04. The consensus estimate for IDEXX Laboratories’ current full-year earnings is $11.93 per share. Leerink Partnrs also issued estimates for IDEXX Laboratories’ Q4 2025 earnings at $2.82 EPS and FY2025 earnings at $12.04 EPS.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. During the same period in the prior year, the firm earned $2.71 EPS. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis.

Several other research firms have also recently commented on IDXX. Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Piper Sandler upped their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Bank of America lifted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 12th. Finally, Stifel Nicolaus reduced their price objective on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating on the stock in a report on Monday, April 14th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $524.75.

IDEXX Laboratories Stock Down 0.3 %

IDEXX Laboratories stock opened at $473.71 on Monday. The firm has a market capitalization of $38.39 billion, a P/E ratio of 44.40, a P/E/G ratio of 3.41 and a beta of 1.52. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories has a twelve month low of $356.14 and a twelve month high of $548.88. The stock’s fifty day simple moving average is $420.26 and its 200-day simple moving average is $428.49.

Institutional Trading of IDEXX Laboratories

Institutional investors and hedge funds have recently bought and sold shares of the business. Insight Wealth Strategies LLC increased its position in IDEXX Laboratories by 230.5% in the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock valued at $4,174,000 after acquiring an additional 7,041 shares during the period. Sax Wealth Advisors LLC lifted its position in IDEXX Laboratories by 76.3% during the 4th quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company’s stock worth $590,000 after acquiring an additional 617 shares during the period. Hantz Financial Services Inc. grew its stake in shares of IDEXX Laboratories by 11.5% in the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company’s stock valued at $3,199,000 after purchasing an additional 800 shares during the last quarter. Paragon Capital Management Inc. increased its holdings in shares of IDEXX Laboratories by 25.7% in the fourth quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company’s stock valued at $1,579,000 after purchasing an additional 782 shares during the period. Finally, Manitou Investment Management Ltd. raised its stake in shares of IDEXX Laboratories by 491.0% during the fourth quarter. Manitou Investment Management Ltd. now owns 52,202 shares of the company’s stock worth $21,582,000 after purchasing an additional 43,369 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.